Pfizer Halts Danuglipron Obesity Pill Trials
April 14, 2025
-
3 min
5 Key Takeaways
-
1
Pfizer discontinues development of the weight-loss agent danuglipron due to suspected drug-induced liver injury in a clinical trial.
-
2
The discontinuation impacted stock prices and may prompt Pfizer to pursue partnerships.
-
3
Danuglipron was being tested as a potential more convenient alternative in the competitive weight-loss drug market.
-
4
Novo Nordisk's Wegovy and Eli Lilly's Zepbound currently dominate the market.
-
5
Pfizer may focus on its investigational oral agent targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR).
Pfizer has discontinued the development of danuglipron, a potential weight-loss agent, due to a suspected drug-induced liver injury in a clinical trial participant. The company had been testing multiple doses of the oral drug as a more convenient alternative in the competitive weight-loss drug market. This discontinuation has led to significant stock movement and may prompt Pfizer to pursue partnerships in the near term.
Listen Tab content
